Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AGI Therapeutics PLC

Division of Horizon Therapeutics PLC

Latest From AGI Therapeutics PLC

Questcor Pharmaceuticals makes appointments

Questcor Pharmaceuticals (US) has appointed Dr David Young, currently a member of the company's board of directors, to the newly created position of chief scientific officer, and has appointed Dr Sian Bigora to the newly created position of vice-president of regulatory affairs. Dr Young joins Questcor from AGI Therapeutics, where he had served as executive director and president of US operations since 2006. Dr Bigora also joins from AGI Therapeutics, where she was vice-president of clinical research and regulatory affairs. Both executives will be based at the company's new east coast offices in Columbia, Maryland.


Pharma's R&D Heartburn Spells Opportunity for GI-Focused Biotechs

Some Big Pharma have looked at the risk-reward equation for gastrointestinal R&D and they have opted out. But GI still represents a massive opportunity for Big Pharma, both in terms of its traditional primary care strengths and more recent forays into specialist medicine. This combination should open up new doors for GI-focused biotech players, several of which feel they can succeed where pharma has failed in tricky areas like IBS, with next generation drugs. Others have hitched their stars to commercially unvalidated targets, exploring new and potentially lucrative mechanisms of action.
BioPharmaceutical Strategy

Deals Shaping the Medical Industry (10/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Fighting for the Exit in Biotech IPOs

Biotech IPOs continue to get done, but not at valuations private investors would prefer.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Alias(es)
  • AGI Therapeutics Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Horizon Therapeutics PLC
  • Senior Management
  • John Devane, PhD, CEO
    David Kelly, CFO
    Patrick Ashe, SVP, Bus. Dev.
  • Contact Info
  • AGI Therapeutics PLC
    Phone: (353) 449 3250
    Adelaide Chambers, Peter St.
    Dublin 8,